A
Alison Church
Researcher at Research Triangle Park
Publications - 35
Citations - 1497
Alison Church is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Vilanterol & Population. The author has an hindex of 17, co-authored 35 publications receiving 1375 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
TL;DR: Once-daily UMEC/VI 62.5/25 mcg was well tolerated and provided clinically-significant improvements in lung function and symptoms in patients with COPD.
Journal ArticleDOI
Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials
Marc Decramer,Antonio Anzueto,Edward Kerwin,Thomas Kaelin,Nathalie Richard,Glenn Crater,Maggie Tabberer,Stephanie Harris,Alison Church +8 more
TL;DR: In both studies, the primary efficacy endpoint of both studies was trough forced expiratory volume in 1 s (FEV1) on day 169, which was analysed in the intention-to-treat population and noted improvements in trough FEV1 on day169 for both doses of UMEC plus VI compared with TIO monotherapy.
Journal ArticleDOI
Once-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPD: A Randomized, Controlled Study
Bartolome R. Celli,Glenn Crater,Sally Kilbride,Rashmi Mehta,Maggie Tabberer,Chris Kalberg,Alison Church +6 more
TL;DR: Once-daily Umeclidinium/vilanterol 125/25 mcg was well tolerated and provided greater improvements in lung function, health status, and dyspnea scores compared with monotherapy components and placebo over 24 weeks, and supports the use of UMEC/VI 125/ 25 mcg for the maintenance treatment of COPD.
Journal ArticleDOI
Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: Results of a 24-week, randomized, controlled trial
TL;DR: UMEC/VI was associated with statistically significant and clinically meaningful improvements in lung function versus TIO and could provide an effective new treatment option for patients with moderate-to-very severe COPD.
Journal ArticleDOI
Umeclidinium in patients with COPD: a randomised, placebo-controlled study
TL;DR: Umeclidinium significantly improves lung function, dyspnoea and health status and is well tolerated in chronic obstructive pulmonary disease patients over 12 weeks.